Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Friday.

AGIO has been the topic of a number of other research reports. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Scotiabank increased their price target on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a research report on Friday. Royal Bank of Canada reissued an “outperform” rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a research report on Friday. Finally, Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $52.33.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $44.87 on Friday. The company has a market cap of $2.55 billion, a P/E ratio of -6.90, a P/E/G ratio of 0.47 and a beta of 0.75. The stock has a 50-day moving average of $44.62 and a two-hundred day moving average of $42.13. Agios Pharmaceuticals has a 1-year low of $20.40 and a 1-year high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The business had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.51) EPS. On average, analysts anticipate that Agios Pharmaceuticals will post 7.54 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AGIO. Caxton Associates LP lifted its stake in Agios Pharmaceuticals by 0.7% in the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after buying an additional 264 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Agios Pharmaceuticals by 0.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,148,000 after acquiring an additional 314 shares during the period. CANADA LIFE ASSURANCE Co raised its position in Agios Pharmaceuticals by 1.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock valued at $911,000 after purchasing an additional 540 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter worth $37,000. Finally, Quest Partners LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter worth $40,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.